Valparaiso, INNCT06717698Now EnrollingIRB Ready

Chronic Kidney Disease Clinical Trial in Valparaiso, IN

Access cutting-edge chronic kidney disease treatment through this phase 2 clinical trial at a research site in Valparaiso. Study-provided care at no cost to qualified participants.

Sponsored by Novo Nordisk A/S

Quick Self-Assessment

See if you qualify for this Valparaiso location

Preparing your pre-screening questions…

Expert Care in Valparaiso

Access chronic kidney disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic kidney disease treatment provided free

Apply for This Valparaiso Location

Check if you qualify for this chronic kidney disease clinical trial in Valparaiso, IN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Valparaiso

    Convenient for IN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Valparaiso site if eligible
  4. 4Begin participation

About This Chronic Kidney Disease Study in Valparaiso

The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study wil

Sponsor: Novo Nordisk A/S

Who Can Participate

Inclusion Criteria

Female of non-childbearing potential, or male.
For US only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency at least 2 months prior to screening and willingness to continue using it through-out the study, or male.
Age 18 years or above at the time of signing the informed consent.
Diagnosed with type 2 diabetes mellitus greater than or equal to (≥) 180 days before screening, or not diagnosed with type 2 diabetes mellitus.
HbA1c of 6.5 percentage (%)-10.5 percentage (%) \[48 - 91 millimoles per mole (mmol/mol)\] (both inclusive) if diagnosed with type 2 diabetes mellitus, or HbA1c of less than (\<)6.5 percentage (%) \[\<48 mmol/mol\] if not diagnosed with type 2 diabetes mellitus.
BMI greater than or equal to (≥) 27.0 kilogram per square metre (kg/m\^2) at screening.
Kidney impairment defined by serum creatinine and cystatin C-based Egfr greater than or equal to (≥) 15 and less than (\<) 90 mL/min/1.73 m\^2.
Albuminuria defined by Urine Albumin-to-Creatinine Ratio (UACR) greater than or equal (≥)100 and less than (\<) 5000 milligram per gram (mg/g).
Treatment with maximum labelled or tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or not tolerated, in the opinion of the investigator. Treatment dose must be stable for at least 30 days prior to screening.

Exclusion Criteria

Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective non-systemic contraception with low user-dependency.
Lupus nephritis or antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Receiving immunosuppressive therapy for primary or secondary renal disease within 6 months prior to screening.
Use of any glucagon-like peptide-1 (GLP-1) RA (including medication with GLP-1 RA activity, e.g., GIP/GLP-1 RA) within 90 days prior to screening.
Myocardial infarction, stroke, transient ischaemic attack, or hospitalization for unstable angina pectoris within 180 days before screening.
Chronic or intermittent haemodialysis or peritoneal dialysis within 90 days before screening.
Only applicable for participants with type 2 diabetes (T2D): Uncontrolled and potentially unstable diabetic retinopathy or diabetic maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Presence or history of malignant neoplasms or in situ carcinomas (other than basal or squamous cell skin cancer, low-risk prostate cancer, or in-situ carcinomas of the cervix or carcinoma in situ/high grade prostatic intraepithelial neoplasia (PIN)) within 5 years before screening.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Valparaiso?

Yes, this clinical trial (NCT06717698) has an active research site in Valparaiso, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Kidney Disease Treatment Options in Valparaiso, IN

If you're searching for chronic kidney disease treatment options in Valparaiso, IN, this clinical trial (NCT06717698) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Valparaiso research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced chronic kidney disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic kidney disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Valparaiso, IN

See all ankylosing spondylitis clinical trials recruiting in Valparaiso — not just this study.

Browse Ankylosing Spondylitis Trials in Valparaiso →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsChronic Kidney Disease TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Valparaiso?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Valparaiso, IN